TEST:

Breast Cancer Index®

No breast cancer index needed. B21 gave us this answer years ago, EUROPA and others will give us average treatment effect for 5 y vs 5 days in terms of QoL. We had just better beware of bad biomarker research for breast (alliteration, ☑️) ()

Watch Chair of Medicine Ruth O'Regan, MD, (@oreganruth) discuss using the #BreastCancer Index as a prognostic tool, and phase 3 SOFT trials for patients with HR+ breast cancer. @OncLive @WilmotCancer #Oncology https://t.co/ZM9nkauu4R ()

The Breast Cancer Index test reliably identified premenopausal women undergoing adjuvant endocrine therapy for early-stage, HR+ breast cancer who would derive benefit from the addition of ovarian function suppression. @oreganruth @UR_Med #bcsm https://t.co/Aahqqnudcs ()

The Breast Cancer Index test reliably identified premenopausal women undergoing adjuvant endocrine therapy for early-stage, HR+ breast cancer who would derive benefit from the addition of ovarian function suppression. @oreganruth @UR_Med #bcsm https://t.co/AalMezysDv ()

In the SOFT trial, the BCI test accurately identified premenopausal women undergoing adjuvant endocrine therapy for early-stage, HR+ breast cancer who would derive benefit from adding ovarian function suppression. #bcsm #SABCS22 | @oreganruth @jenreadlynn https://t.co/oehv4LIOje ()

Breast Cancer Index: Predict Treatment SABCS 2022 Ruth O'Reagan - What Can the SOFT Trial Reveal For Premenopausal Women with Early-Stage HR+ Breast Cancer? @oreganruth @URMC_DeptMed #SABCS22 #BreastCancer #OncoTwitter Watch and Share the Article Here: https://t.co/0sBipwZyaL ()

Make your way to the back of the #SABCS exhibit hall to hear from Dr. Young, @DrVKGadi and @oreganruth on the predictive power of the Breast Cancer Index H/I Biomarker! ()

#BreastCancer Index Risk Scores Are Prognostic for Premenopausal Women With HR+ Breast Cancer Receiving Adjuvant Endocrine Therapy #URochesterResearch from chair of Medicine @oreganruth, featured in @OncLive ()

Ruth O’Regan, MD, on Evaluation of the Breast Cancer Index in Early-Stage Breast Cancer https://t.co/jd2KZxSYFm #bcsm #breastcancer #oncology #SABCS22 #SABCS2022 @SABCSSanAntonio @oreganruth @URMC_DeptMed @URMC_Medicine ()

Breast Cancer Index: Predict Treatment SABCS 2022 Ruth O'Reagan - What Can the SOFT Trial Reveal For Premenopausal Women with Early-Stage HR+ Breast Cancer? @oreganruth @URMC_DeptMed #SABCS22 #BreastCancer #OncoTwitter Watch and Share the Video Here: https://t.co/Mpy9nG9cHG ()

Breast Cancer Index Risk Scores Are Prognostic for Premenopausal Women With HR+ Breast Cancer Receiving Adjuvant Endocrine Therapy @oreganruth @UR_Med @SABCSSanAntonio #SABCS #bcsm https://t.co/g8AKZrc83K ()

術後内分泌療法を受けた閉経前ホルモン受容体陽性 #乳がん で、遺伝子発現に基づくバイオマーカーである #BreastCancerIndex ()

6. Breast Cancer Index in premenopausal, HR+, LN -from SOFT trial by @oreganruth from @WilmotCancer - Prognostic tool - OFS +ET benefits most in BCI low risk premenopausal patients - What would you do for BCI high-risk? - Poll by @DrSGraff https://t.co/LzxTNwQuN6 8/11 ()

@oreganruth of @URMC_DeptMed shared results from the “Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial” #SABCS22 ()

I had the opportunity of participating at the conference “Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial” in the General Session 1 this evening at @SABCSSanAntonio , Incredible work by MD Ruth M. O’Regan. 🙌🏼👏🏼🩺 ()

#BCI Breast Cancer Index prediction benefit for extended endocrine therapy and prevention late recurrence: #SOFT trial @oreganruth #SABCS2022. May be very helpful marker to decide extended Endocrine therapy @pollyniravath ()

…I’m a bit confused here on prognostic & predictive value of #BreastCancer Index in premenopausal patients enrolled in #SOFT trial…need help from experts: results are the opposite than expected @SABCSSanAntonio #SABCS22 @OncoAlert @prat_aleix @c_sotiriou @DrHBurstein @LoiSher ()

BCI assay in SOFT. BCI low (all low grade) 🔼 benefit from OFS/AI. BCI high do not. @hoperugo makes important point in Q&A, however. Hard to reconcile with IDEAL study (longer ET 🔼BCI high), or fit with 🔼 benefit to OFS in biologically higher risk tumors. #SABCS22 ()

Hard to explain results of Breast cancer index as a predictive biomarker of OFS in SOFT trial. BCI is predictive of OFS benefit for BCI-Low tumo but not for BCI-High. #SABCS2022 ()

@oreganruth presenting on Breast Cancer Index in premenopausal patients with HR+ BC from SOFT trial. BCI(H/I) LOW predictive for benefit from E+OFS vs T+OFS but BCI (H/I) HIGH not predictive. #SABCS22 ()

Breast cancer index and SOFT trial . Can we predict who will benifit more from OFS ? @OncoAlert @SABCSSanAntonio #sabcs22 ()

The Breast Cancer Index genomic assay may predict long-term prognosis and benefit from ovarian suppression therapy in premenopausal patients with hormone receptor-positive early-stage breast cancer, according to results presented at #SABCS22. https://t.co/0z3jIuwK2i @oreganruth ()

How can Breast Cancer Index help inform treatment decisions? Drs. Joyce O'Shaughnessy (@BCJoyceO), Mark Pegram, and @DrVKGadi discuss a challenging case for consideration in recommending extended endocrine therapy: https://t.co/37PkCNswwQ #breastcancerindex #casestudy ()

Risk of recurrence is independent of whether a patient is likely to benefit from extended endocrine therapy. Drs. Mark Pegram, @DrVKGadi and @BCJoyceO discuss: https://t.co/hW2vgUG3Sj #breastcancerindex #casestudy ()

Watch Drs. Joyce O’Shaughnessy @BCJoyceO, Mark Pegram, and @DrVKGadi discuss management and treatment options for a case in which Breast Cancer Index identifies an older patient who is likely to benefit from continuing endocrine therapy beyond year 5: https://t.co/HBfrrtcU4d ()

Breast Cancer Index is the only commercially available, guideline recognized test to predict likelihood of benefit of extended endocrine therapy. Hear more from Dr. Joyce O'Saughnessy. @BCJoyceO #breastoncology #breastcancertreatment ()

New blog featuring Dr. Raquel Nunes, author of a study examining the predictive usefulness of the Breast Cancer Index in assessing the risk of #lobular #breastcancer recurrence. https://t.co/IEXcZGSypY @Otto_DFCI @oesterreichs @double_whammied @LPseattle #IHaveLOBULARBreastCancer ()

For the problem at hand ⁦@DhakalAjay⁩ presents the past data on endocrine therapy and a future plan for deescalation with chair ⁦@CARLAISADORA⁩ ⁦@OncLiveSOSS⁩ #ipc #breastcancer #bcsm ⁦@URMC_Medicine⁩ ⁦@WilmotCancer⁩ breast cancer index predictive? (@donnashort)

So take home message for those relying on BCI (breast cancer index) to help guide therapy? #bcsm (@DrAttai)

Dr, Mamounas presenting results from NRG Oncology/ NSABP B-42 and Breast Cancer Index prediction of benefit from extended AI therapy. #ASCO21. ⁦@NRGonc⁩ (@TBJulianMD)

Mamounas NSABP B-42 Breast Cancer Index and extended adjuvant endocrine therapy. Quick take: in contrast to prior studies, BCI doesn’t predict benefit of extended ET. Lots of negative interaction tests. #ASCO2021 (@GeorgeSledge51)

I think there are very few women who don’t benefit from Breast Cancer Index testing at five years, except the extremely low risk and the extremely high risk—most women are in the middle and all of these women appreciate the personalized information—could save them 5 yrs of AIs (@shycollie)

Curious what you think of the value of tests like the Breast Cancer Index in managing risk/benefits of long-term hormonal therapies? (@Shanna_Marzilli)